NCT04786990 - Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

May 23, 2023

Study Completion Date

July 26, 2023

Conditions

Attention-Deficit/Hyperactivity Disorder (ADHD)

Interventions

DRUG

SPN-812

Viloxazine extended-release capsule

Trial Locations (17)

29405

Coastal Carolina Research Center, North Charleston

32803

APG Research, LLC, Orlando

33155

Miami Clinical Research, Miami

47715

Qualmedica Research, LLC, Evansville

63304

Midwest Research Group, Saint Charles

66221

Psychiatric Associates Purehealth Medical Center, Overland Park

68526

Alivation Research, LLC, Lincoln

72211

Preferred Research Partners, Inc., Little Rock

73112

SP Research, PLLC, Oklahoma City

77381

Family Psychiatry of The Woodlands, The Woodlands

77702

Gadolin Research, LLC, Beaumont

83221

Elite Clinical Trials, Blackfoot

83440

Elite Clinical Trials, Rexburg

89128

Center for Psychiatry and Behavioral Medicine, Las Vegas

92868

NRC Research Institute, Orange

98007

Northwest Clinical Research Center, Bellevue

00926

Barbara Diaz Hernandez MD Research, INC., San Juan

All Listed Sponsors

lead

Supernus Pharmaceuticals, Inc.

INDUSTRY